leisure time -WSS

leisure time

author：hotspot 2025-09-29 19:04:57 - browse：925

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

knowledge

WSS

As AI in medicine takes off, can 'human in the loop' prevent harm?

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

Change Healthcare outage fallout shows need for new oversight

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

Continuity nursing helped my family in our darkest PICU moments

FDA advisers back CAR

Continuity nursing helped my family in our darkest PICU moments

Pentagon will tighten controls on classified information after Discord leak

As demand for Covid shots wanes, Moderna seeks its next success

5 shark bites reported on Long Island as officials deploy surveillance drones

Supreme Court strikes down use of affirmative action

Boston's new lab space is opening empty

entertainment

Ebola: Gilead Sciences antiviral shows promise as new treatment

Boston's new lab space is opening empty

President Biden's budget: Here's what you might have missed

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Israel withdraws forces after 2

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

knowledge

leisure time

entertainment

Wikipedia